DAX ®12.614,71-1,71%TecDAX ®2.796,13-1,87%S&P FUTURE2.744,50-1,27%Nasdaq 100 Future7.183,75-1,27%
finanztreff.de
WM Tippspiel
teilnehmen und gewinnen
finanztreff.de

Hardman & Co Research: Evgen Pharma (EVG): Encouraging interim data from the STEM trial

| Quelle: DGAP | Lesedauer etwa 3 min. | Text vorlesen Stop Pause Fortsetzen

Hardman & Co Research
Hardman & Co Research: Evgen Pharma (EVG): Encouraging interim data from the STEM trial

13-Jun-2018 / 14:14 GMT/BST


Hardman & Co Research: Encouraging interim data from the STEM trial

Evgen (EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. EVG has created new and stable variants of sulforaphane using its proprietary technology, Sulforadex, enabling it to be used as a therapeutic for the first time. SFX-01 is currently in Phase II trials for both subarachnoid haemorrhage (SAH) and ER+ breast cancer, with read-outs expected around the end of 2018. Meanwhile, EVG has disclosed positive interim data from its STEM trial in metastatic breast cancer. Please click here for the full report:

http://www.hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/13.06.18-encouraging-interim-data-from-the-stem-trial.pdf?dm_i=49CL,AD0Q,1QPFG3,14VT4,1

 

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH
www.hardmanandco.com
Follow us on Twitter @HardmanandCo
Contacts:

Grégoire Pavé

+44 20 7194 7628


gp@hardmanandco.com
 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

695127  13-Jun-2018 

fncls.ssp?fn=show_t_gif&application_id=695127&application_name=news&site_id=real_vwd
Werbung
Werbung

News-Suche

Suchbegriff:
Werbung

Aktuelle Videos

zur Mediathek
Werbung
Börsenseminare: Investieren Sie in Ihre Bildung!
Werbung

Werbung
Börse Stuttgartschliessen
Börse Stuttgart

Top-Wachstumsaktien

Wo bieten sich Anlegern weltweit die besten Wachstumschancen? Wir stellen im neuen Anlegermagazin vier Titel mit viel Potenzial vor.

Jetzt kostenlos anmelden!
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook, Google+ oder Twitter
Aktuelle Umfrageschliessen
Haben Sie schon einmal von wikifolio gehört?
Jetzt abstimmen!
Alle Umfragen ansehen
schliessen